TWD 179.0
(-1.65%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 2.39 Billion TWD | -13.68% |
2022 | 2.77 Billion TWD | 41.39% |
2021 | 1.96 Billion TWD | 28.7% |
2020 | 1.52 Billion TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 905.07 Million TWD | 10.92% |
2024 Q1 | 815.94 Million TWD | 18.48% |
2023 Q4 | 688.65 Million TWD | 6.34% |
2023 FY | 2.39 Billion TWD | -13.68% |
2023 Q3 | 647.57 Million TWD | 20.9% |
2023 Q2 | 535.62 Million TWD | 1.86% |
2023 Q1 | 525.82 Million TWD | -23.3% |
2022 FY | 2.77 Billion TWD | 41.39% |
2022 Q4 | 685.53 Million TWD | 0.0% |
2021 FY | 1.96 Billion TWD | 28.7% |
2020 FY | 1.52 Billion TWD | 0.0% |
2019 FY | - TWD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 2.15 Billion TWD | -11.508% |
Maxigen Biotech Inc. | 622.11 Million TWD | -285.407% |
SciVision Biotech Inc. | 712.98 Million TWD | -236.285% |
Bionime Corporation | 1.75 Billion TWD | -36.576% |
Pegavision Corporation | 6.78 Billion TWD | 64.687% |